Hydroxychloroquine reduces low-density lipoprotein cholesterol levels in systemic lupus erythematosus: a longitudinal evaluation of the lipid-lowering effect

Abstract

This longitudinal study demonstrated the beneficial effect of antimalarials on lipids in SLE since this therapy induced a reduction of atherogenic lipoproteins.

Associations of Hydroxychloroquine Use With Lipid Profiles in Rheumatoid Arthritis: Pharmacologic Implications

“…The added lipidlowering benefit of HCQ in rheumatic diseases is well documented (32,33), including in RA (19). Our findings were similar; HCQ had independent associations with lower lipid values, save for the nonsignificant elevation of HDL.…”

“…HCQ users met NCEP-ATP III lipid target levels for TC, LDL, and combined LDL and HDL values. Current longitudinal studies of the lipid-lowering effects of HCQ are unblinded, are of small numbers as in systemic lupus erythematosus, or, in RA, include additional DMARDs in post-hoc analyses (15,32). Our VA pharmacy administrative data permitted evaluation of HCQ-lipid associations over various periods of drug exposure, an analysis not previously described.…”

The Effect of Hydroxychloroquine Treatment on Blood Sugar Level, Serum Lipid Profile and the Retina in Systemic Lupus Erythematosus Patients

“…So, there was a significant difference between the patients before and after taking HCQ treatment [6][7][8]28]. …”

“…At 12 months after treatment, the levels of two lipid TC and HDL parameters had fully recovered to the normal limits [6][7][8].…”

Hydroxychloroquine in Systemic Lupus Erythematosus: Comment on the Article by Muangchan et al

“…Antimalarials have additional beneficial effects in SLE patients: HCQ is associated with lower serum cholesterol levels (11)(12)(13)(14), higher bone mineral density (15,16), and HCQ protects against future thrombotic events (7,17,18).…”